Skip to content

Scientific publications

  • article Arneaud A, Rivest S, Laflamme N

    The Therapeutic Role of Monocytes in Alzheimers Disease: Effects on Vascular Amyloid-Beta Transport

    Alzheimers Dement 21 Suppl 5 (Suppl 5), 2025.

    DOI PUBMED
  • article Lin E, Cruz-Marino T, Chrestian N, Leblanc J, Rioux N, Labrie Y, Rivest S, Lace B, Colaiacovo S, Saleh M

    Describing the First Canadian Cohort of Oculogastrointestinal Neurodevelopmental Syndrome Caused by CAPN15 Pathogenic Variants

    Am J Med Genet A 197 (10), 2025.

    DOI PUBMED
  • article Ghareghani M, Arneaud A, Rivest S

    The evolution of mesenchymal stem cell-derived neural progenitor therapy for Multiple Sclerosis: from concept to clinic

    Front Cell Neurosci 18 2024.

    DOI PUBMED
  • article Martínez-Drudis L, Bérard M, Musiol D, Rivest S, Oueslati A

    Pharmacological inhibition of PLK2 kinase activity mitigates cognitive decline but aggravates APP pathology in a sex-dependent manner in APP/PS1 mouse model of Alzheimer’s disease

    Heliyon 10 (20), 2024.

    DOI PUBMED
  • article Lapeyre L, Piret J, Rhéaume C, Pons V, Uyar O, Préfontaine P, Rivest S, Boivin G

    Herpes Simplex Virus 1 Infection Does Not Increase Amyloid-β Pathology in APP/PS1 Mice

    J Alzheimers Dis 97 (1), 2024.

    DOI PUBMED
  • article Ghareghani M, Rivest S

    Multiple Sclerosis Research Evolves: A Closer Look at Deep Gray Matter, Sexual Function Rehabilitation, and T Regulatory Cells

    J Pers Med 14 (2), 2024.

    DOI PUBMED
  • article Ghareghani M, Rivest S

    The Synergistic Potential of Combining PD-1/PD-L1 Immune Checkpoint Inhibitors with NOD2 Agonists in Alzheimer’s Disease Treatment

    Int J Mol Sci 24 (13), 2023.

    DOI PUBMED
  • article Ghareghani M, Zibara K, Rivest S

    Melatonin and vitamin D, two sides of the same coin, better to land on its edge to improve multiple sclerosis

    Proc Natl Acad Sci U S A 120 (14), 2023.

    DOI PUBMED
  • article Ghareghani M, Pons V, Laflamme N, Zibara K, Rivest S

    Author Correction: Inhibiting nighttime melatonin and boosting cortisol increase patrolling monocytes, phagocytosis, and myelination in a murine model of multiple sclerosis

    Exp Mol Med 55 (2), 2023.

    DOI PUBMED
  • article Ghareghani M, Pons V, Laflamme N, Zibara K, Rivest S

    Inhibiting nighttime melatonin and boosting cortisol increase patrolling monocytes, phagocytosis, and myelination in a murine model of multiple sclerosis

    Exp Mol Med 55 (1), 2023.

    DOI PUBMED
  • article Piec PA, Pons V, Préfontaine P, Rivest S

    Muramyl Dipeptide Administration Delays Alzheimer’s Disease Physiopathology via NOD2 Receptors

    Cells 11 (14), 2022.

    DOI PUBMED
  • article Martínez-Drudis L, Sheta R, Pellegrinato R, Loukili S, Tremblay C, Calon F, Rivest S, Oueslati A

    Inhibition of PLK2 activity affects APP and tau pathology and improves synaptic content in a sex-dependent manner in a 3xTg mouse model of Alzheimer’s disease

    Neurobiol Dis 172 2022.

    DOI PUBMED